Monday, 7 October 2019

Renaissance of letrozole from anticancer drug to Ovulation inducing agents (more effective than CC


What is letrozole “The Queen of Aromatase inhibitors”  : What was the original indication? Ans:- Letrozole is an oral non-steroidal aromatase inhibitor approved by US Food and Drug Administration ( FDA) for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Off-label it has been used for ovarian stimulation in assisted reproduction since 2001 and later it was banned in some courtiers as the Queen was in love with some other gentleman and this is not approved in the ethics and of late religion in our country!!! .


What happened in the new century ? Defamation of Queen:- She is bad unkind Queen, Ban her !!! Few researchers  misguided the entire world that letrozole was associated with increased risks of birth defects and was therefore  banned as ovulation induction in many countries including India since 2011, following reports of 2 studies citing increase incidences of congenital malformations (locomotor and cardiac abnormalities).

Did U K listened to such defamation of our Lady Queen(Letrozole)?? One such study was presented at the  American Society of  Reproductive Medicine 2005 Conference But, such off-label use of Letrozole for ovarian stimulation was not declared   illegal in USA and UK.  It was continued to be used  as an ovulation induction agent in ARTs Exciting developments: To their surprise they   observed that Letrozole induced ART pregnancies had 1)  risk of miscarriage,2)  with no increase in the risk of major congenital anomalies or 3)  adverse pregnancy or 4)  neonatal outcomes compared with natural cycles in women undergoing ART!!!


No comments:

Post a Comment